Home

Join the Discussion

Connect

Build community with your colleagues in our new space for knowledge exchange and professional networking.


Connect

 

Learn

Build a knowledge base of industry best practices, sample documents and more in our resource library.


Learn

 

Explore

Ask questions of your peers to gain the tools you need to communicate with leaders and partners in your field. 


Explore

 

Latest Discussions

  • Posted in: Member Community

    I just wanted to give one follow-up if I could. In the BMJ publication the following quote appears. "…there was a noticeable association between increasing anticholinergic burden over the previous 4-20 years and incident dementia…These relations were ...

  • Posted in: Member Community

    Thanks Pat. So what absolute difference in your composite cure definition between two therapies/procedures would lead you to consider one therapy superior to the other (eg 5%, 10%, 15%)? Nick Abraham (Nick) Morse MD,MBA Chief of Urogynecology, Director ...

  • Posted in: Member Community

    Thanks for your thoughtful response, Dennis. The obvious challenge here is not necessarily the manufacturers of anticholinergic OAB meds but the insurance carriers that mandate their use before considering beta agonists or third line therapies such ...

Upcoming Events


Recent Shared Files